Literature DB >> 17021823

Treatment options for BCG failures.

Michael A O'Donnell1, Andreas Boehle.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17021823     DOI： 10.1007/s00345-006-0112-0

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  53 in total

1.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

Authors:  Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors.

Authors:  Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

3.  Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects.

Authors:  Patrik Andius; Marianne Fehrling; Sten Holmäng
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

4.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

Authors:  P U Malmström; H Wijkström; C Lundholm; K Wester; C Busch; B J Norlén
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

5.  Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.

Authors:  M Brake; H Loertzer; R Horsch; H Keller
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

6.  [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].

Authors:  Yuji Yamada; Isao Hara; Masafumi Kumano; Junnya Furukawa; Kazuki Yamanaka; Sadao Kamidono
Journal:  Hinyokika Kiyo       Date:  2005-08

7.  Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.

Authors:  U O Nseyo; B Shumaker; E A Klein; K Sutherland
Journal:  J Urol       Date:  1998-07       Impact factor: 7.450

8.  Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

Authors:  Guido Dalbagni; Paul Russo; Joel Sheinfeld; Madhu Mazumdar; William Tong; Farhang Rabbani; Machelle S Donat; Harry W Herr; Pramod Sogani; Dominique dePalma; Dean Bajorin
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

9.  Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder.

Authors:  A G van der Heijden; L A Kiemeney; O N Gofrit; O Nativ; A Sidi; Z Leib; R Colombo; R Naspro; M Pavone; J Baniel; F Hasner; J A Witjes
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

10.  Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.

Authors:  H Ovesen; A L Poulsen; K Steven
Journal:  Br J Urol       Date:  1993-11
View more
  26 in total

1.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 2.  Targeted therapies in urothelial carcinoma.

Authors:  Monalisa Ghosh; Sam J Brancato; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

3.  Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer.

Authors:  Omkara L Veeranki; Arup Bhattacharya; Li Tang; James R Marshall; Yuesheng Zhang
Journal:  Curr Pharmacol Rep       Date:  2015-08

4.  Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer.

Authors:  Reema Railkar; L Spencer Krane; Q Quentin Li; Thomas Sanford; Mohammad Rashid Siddiqui; Diana Haines; Srinivas Vourganti; Sam J Brancato; Peter L Choyke; Hisataka Kobayashi; Piyush K Agarwal
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

5.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 6.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 7.  Alternative therapies in patients with non-muscle invasive bladder cancer.

Authors:  Öner Şanlı; Yair Lotan
Journal:  Turk J Urol       Date:  2017-12-01

Review 8.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 9.  Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.

Authors:  Kyla N Velaer; Ryan L Steinberg; Lewis J Thomas; Michael A O'Donnell; Kenneth G Nepple
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

10.  [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Authors:  B A Hadaschik; K Zhang; A I So; J C Bell; J W Thüroff; P S Rennie; M E Gleave
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.